Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Хламидийная инфекция

Список литературы

  1. CDC. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae. 2014. MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports. Centers for Disease Control. 2014;63(RR-02):1-19.
  2. Grad A, Vica ML, Matei HV, Grad DR, Coman I, and Tataru DA. Polymerase Chain Reaction as a Diagnostic Tool for Six Sexually Transmitted Infections - Preliminary Results: Clujul Med. 2015;88(1):33-37.
  3. Knox J, Tabrizi SN, Miller P, et al. Evaluation of self-collected samples in contrast to practitioner-collected samples for detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis by polymerase chain reaction among women living in remote areas. Sex Transm Dis. 2002;29(11):647-654.
  4. Chachter J, Chernesky MA, Willis DE, et al. Vaginal swabs are the specimens of choice when screening for Chlamydia trachomatis and Neisseria gonorrhoeae: Results from a multicenter evaluation of the APTIMA assays for both infections. Sex Transm Dis. 2005;32(12):725-728.
  5. Schachter J, Moncada J, Liska S, Shayevich C, Klausner JD. Nucleic acid amplification tests in the diagnosis of Chlamydial and Gonococcal infections of the oropharynx and rectum in men who have sex with men. Sex Transm Dis. 2008;35(7):637-642.
  6. Mimiaga MJ, Mayer KH, Reisner SL, et al. Asymptomatic gonorrhea and chlamydial infections detected by nucleic acid amplification tests among Boston area men who have sex with men. Sex Transm Dis. 2008;35(5):495-498.
  7. Bachmann LH, Johnson RE, Cheng H, et al. Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis rectal infections. J Clin Microbiol. 2010;48(5):1827-1832.
  8. Шипицына Е.В., Шалепо К.В., Савичева А.М., Домейка М. Научные исследования по оптимизации методов лабораторной диагностики инфекций, передаваемых половым путем. Журнал акушерства и женских болезней. 2007;(5):32-35.
  9. Association of Public Health Laboratories (APHL). Laboratory diagnostic testing for Chlamydia trachomatis and Neisseria gonorrhoeae. Expert consultation meeting summary report. Atlanta, GA. Silver Spring, MD, APHL, 2009; uRLhttp://www.aphl.org/aphlprograms/infectious/std/Documents/ID_2009Jan_CTGCLab-Guidelines-Meeting-Report.pdf.
  10. Horner P et al. Enhanced enzyme immunoassay with negative-gray-zone testing compared to a single nucleic acid amplification technique for community based chlamydial screening of men. Journal of Clinical Microbiology. 2005; 43(5):2065-2069.
  11. Renton A, Filatova E, Ison C, Meheus A, Dmitriev G, Akovbian V, et al. A trial of the validity of genital smears and cultures with gonococcal vaccine provocation in diagnosing genital gonorrhoea in women. Int J STD AIDS. 2009; (20):24-29.
  12. Lau CY, Qureshi AK. Azithromycin versus doxycycline for genital Chlamydial infections: a meta-analysis of randomized clinical trials. Sex Transm Dis. 2002;(29):497-502.
  13. Kong FY, Tabrizi SN, Fairley CK, Vodstrcil LA, Huston WM, Chen M, Bradshaw C, Hocking JS. The efficacy of azithromycin and doxycycline for the treatment of rectal chlamydia infection: a systematic review and meta-analysis. J Antimicrob Chemother. 2015;70(5):1290-7.
  14. Geisler WM, Koltun WD, Abdelsayed N, et al. Safety and efficacy of WC2031 versus vibramycin for the treatment of uncomplicated urogenital Chlamydia trachomatis infection: a randomized, double-blind, double-dummy, active-controlled, multicenter trial. Clin Infect Dis. 2012;(55):82-8.
  15. CDC. Sexually Transmitted Diseases Guidelines; 2014; URL:http://www.cdc.gov/std/treatment/2014/2014-std-guidelines-peer-reviewers-08-20-2014.pdf
  16. European guideline for the management of Chlamydia trachomatis infections 2015. URL http://www.iusti.org/regions/europe/pdf/2015/Chlamydia2015.pdf .
  17. Adimora AA. Treatment of uncomplicated genital Chlamydia trachomatis  infections in adults. Clin Infect Dis. 2002;(35):S183-S186.
  18. Kong FY and Hocking JS. Treatment challenges for urogenital and anorectal Chlamydia trachomatis. BMC Infect Dis. 2015;15:293.
  19. Khosropour CM, Dombrowski JC, Barbee LA, et al. Comparing azithromycin and doxycycline for the treatment of rectal chlamydial infection: A retrospective cohort study. Sex Transm Dis. 2014;41:79-85.
  20. Schwebke JR, Rompalo A, Taylor S, et al. Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens – a randomized clinical trial. Clin Infect Dis. 2011;52:163-170.
  21. .Czeizel AE, Rockenbauer M, Olsen J, Sorensen HT. A case-control teratological study of spiramycin, roxithromycin, oleandomycin and josamycin. Acta Obstet Gynecol Scand. 2000;(79):234-7.
  22. Iakubovich AI, Chuprin AE, Rakitin DA. Urogenital chlamydia infection: treatment with wilprafen. Urologiia. 2003;(1):55-8.
  23. Ibsen HH, Moller BR, Halkier-Sorensen L, et al. Treatment of nongonococcal urethritis: comparison of ofloxacin and erythromycin. Sex Transm Dis. 1989;(16): 32-35.
  24. Maiti H, Chowdhury FH, Richmond SJ, et al. Ofloxacin in the treatment of uncomplicated gonorrhea and chlamydial genital infection. Clin Ther.1991;(13): 441-447.
  25. Mikamo H, Sato Y, Hayasaki Y, Hua YX, Tamaya T. Adequate levofloxacin treatment schedules for uterine cervicitis caused by Chlamydia trachomatis. Chemotherapy. 2000;46(2):150-2. .
  26. Khrianin AA and Reshetnikov OV. Is it safe to use josamycin in the obstetrics practice in Russia? Antibiot Khimioter. 2007;(52):32-36.
  27. Primiero FM, Caruso G, Grottanelli F, et al. Josamycin in the treatment of Chlamydia trachomatis cervicitis. J Chemother. 1989;(1):909-910.
  28. Lucisano A, Vitale AM, Cinque B, et al. Josamycin in the treatment of chlamydial genital infections in infertile women. J Chemother. 1989;(1):906-908.
  29. Molochkov VA, Mostakova NN. Vilprafene (josamycin) therapy of chronic chlamydial prostatitis. Urologiia. 2001;(3):34-5.
  30. Rahangdale L, Guerry S, Bauer HM, Packel L, Rhew M, Baxter R, et al. An observational cohort study of Chlamydia trachomatis treatment in pregnancy. Sex Transm Dis. 2006;(33):106-10.
  31. Brocklehurst P, Rooney G. Interventions for treating genital chlamydia trachomatis infection in pregnancy. Cochrane Database of Systematic Reviews. 2007, Issue 4. Art. No.: CD000054.
  32. Soltz-Szots J, Schneider S, Niebauer B, Knobler RM, Lindmaier A. Significance of the dose of josamycin in the treatment of chlamydia infected pregnant patients. Z Hautkr. 1989;(64):129-31.
  33. Галимова Э.Р. Опыт лечения хламидийной урогенитальной инфекции у беременных вильпрафеном. Актуальные вопросы акушерства и гинекологии. Сб. Научных трудов 2001-2002;1(1).
  34. Darville T. Chlamydia trachomatis infections in neonates and young children. Semin Pediatr Infect Dis. 2005;(16):235-44.
  35. Wang Y, Yang WB, Yuan HY, Zhang QX, Zhu XY. Analysis of the infection status and the drug resistance of mycoplasma and chlamydiae in genitourinary tracts of children with suspected nongonococcal urethritis. Zhonghua Er Ke Za Zhi. 2009;47(1):62-4.
  36. Ведение больных с инфекциями, передаваемыми половым путем, и урогенитальными инфекциями: Клинические рекомендации. Российское общество дерматовенерологов и косметологов. М.: Деловой экспресс, 2012: 112 с.
  37. Hammerschlag MR, Gelling M, Roblin PM, Kutlin A, Jule JE. Treatment of neonatal chlamydial conjunctivitis with azithromycin. The Pediatric infectious disease journal. 1998;7(11):1049-1050.
  38. Kohlhoff CA, Hammerschlag MR. Treatment of chlamydial infections: 2014 update (review). Expert Opin. Pharmacother. 2015;16(2):205-212.
  39. Sexually Transmitted Diseases Treatment Guidelines 2015: Chlamydial Infections. 
  40. Mikamo H, Yamagishi Y, Takahashi K, et al. Clinical study of levofloxacin 500 mg qd in the treatment of cervicitis and intrauterine infections caused by Chlamydia trachomatis. Jpn J Antibiot. 2011;64(4):217-29.
  41. Глобальная стратегия сектора здравоохранения по инфекциям, передаваемым половым путем 2016-2021. https://apps.who.int/iris/bitstream/handle/10665/250268/WHO-RHR-16.09-rus.pdf?sequence=1.
  42. Landers DV, Sweet R.L. Current trends in the diagnosis and treatment of tuboovarian abscess. Am. J. Obstet. Gynecol. 1985;(151):1098-1110. 
  43. Moore KR, Smith JS, Cole SR, Dittmer DP, Schoenbach VJ, Baird DD. Chlamydia trachomatis Seroprevalence and Ultrasound-Diagnosed Uterine Fibroids in a Large Population of Young African-American Women. Am J Epidemiol. 2018;187(2):278-286.
  44. Honkila M, Wikström E, Renko M, et al. Probability of vertical transmission of Chlamydia trachomatis estimated from national registry data. Sex Transm Infect. 2017;93(6):416-420.
  45. Бекарова  А.М. Хламидийная инфекция у новорожденных и детей первого года жизни. Диссертация на соискание ученой степени кандидата медицинских наук, 2003 г.
  46. Виноградова И.В. Эпидемиология, диагностические критерии и течение хламидийной инфекции у новорожденных детей. Диссертация на соискание ученой степени кандидата медицинских наук, 2004 г.
  47. Буданов П.В. Актуальные проблемы лечения беременных с рецидивирующей хламидийной инфекцией. Лечащий врач, 2007;(10):21-5.
  48. Páez-Canro C, Alzate JP, González LM, Rubio-Romero JA, Lethaby A, Gaitán HG. Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non-pregnant women. Cochrane Database Syst Rev. 2019;1(1):CD010871. Published 2019 Jan 25.
  49. Geisler WM, Uniyal A, Lee JY, Lensing SY, Johnson S, Perry RCW, Kadrnka CM and Kerndt PR. Azithromycin versus doxycycline for urogenital chlamydia trachomatis infection. N Engl J Med. 2015;373:2512-2521.
  50. WHO Guidelines for the Treatment of Chlamydia trachomatis. 2016. URL: https://www.ncbi.nlm.nih.gov/books/NBK379707/pdf/Bookshelf_NBK379707.pdf
  51. Nicole HT, Dukers-Muijrers M, Petra F, Wolffs G, De Vries H, Götz HM, Heijman T, Bruisten S, Eppings L, Hogewoning A, Steenbakkers M, Lucchesi M, Schim van der Loeff MF, Christian J P A Hoebe. Treatment effectiveness of azithromycin and doxycycline in uncomplicated rectal and vaginal Chlamydia trachomatis infections in women: A multicenter observational study (FemCure). Clinical Infectious Diseases. 2019;69(1):1946-1954.
  52. Karl E Miller. diagnosis and treatment of Chlamydia trachomatis infection. Am Fam Physician. 2006;73(8):1411-1416.
  53. Kong FY, Tabrizi SN, Law M, et al. Azithromycin versus doxycycline for the treatment of genital Chlamydia infection: A meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;59:193-205.
  54. Takahashi S, Ichihara K, Hashimoto J, et al. Clinical efficacy of levofloxacin 500 mg once daily for 7 days for patients with nongonococcal urethritis. J Infect Chemother. 2011;17:392-6.
  55. Lanjouw E, Ossewaarde JM, Stary A, Boag F. European guideline for the management of Chlamydia trachomatis infections. 2010. URL: https://www.aslimnica.lv/sites/default/files/editor/euro_guideline_chlamydia_2010.pdf
  56. Carter JD and Hudson AP. The evolving story of Chlamydia-induced reactive arthritis. Curr Opin Rheumatol. 2010;(22):424-430.
  57. Bojovic J, Strelic N and Pavlica L. Reiter’s syndrome – disease of young men – analysis of 312 patients. Med Pregl. 2014;(67):222-230.
  58. CDC 2015. Sexually transmitted infections treatment guidelines. Pelvic Inflammatory Disease. URL. https://www.cdc.gov/std/tg2015/pid.htm.
  59. Белоусов Ю.Б., Карпов О.И., Белоусов Д.Ю. Клинико-экономическое обоснование применения вильпрафена в лечении урогенитального хламидиоза.  Качественная клиническая практика. 2006;(1):64-75.
  60. Tan AK. Ophthalmia Neonatorum. N Engl J Med. 2019;380(2):e2. doi: 0.1056/NEJMicm1808613.
  61. Jin J. Prevention of Gonococcal Eye Infection in Newborns. JAMA. 2019;321(4):414.
  62. Zikic A. et al. Treatment of neonatal chlamydial conjunctivitis: A systematic review and meta-analysis. Journal of the Pediatric Infectious Diseases Society.  2018;7(3):e107-e115.
  63. British Association of Sexual Health and HIV. 2014 Draft UK national guideline for the management of genital infection with Chlamydia trachomatis, http:// www.bashh.org/BASHH/Guidelines/Guidelines/BAS HH/Guidelines/Guidelines.aspx?hkey=072c83ed-0e9b44b2-a989-7c84e4fbd9de (2013, accessed 15 August 2015).
  64. European Branch of the International Union against Sexually Transmitted Infections (IUSTI Europe) and the European Office of the World Health Organisation (WHO-Europe).
  65. Савенкова М.С., Афанасьева А.А. Хламидиоз у детей. Современные аспекты лечения. Эффективная фармакотерапия. 2012;(53):6-13.
  66. Workowski KA, Lampe MF, Wong KG et al. Long-term eradication of Chlamydia trachomatis genital infection after antimicrobial therapy evidence against persistent infection. JAMA. 1993;270(17):2071-2075.
  67. Taylor-Robinson D and Keat A. Observations on Chlamydia trachomatis and other microbes in reactive arthritis. Int J STD AIDS. 2015;(26):139-144.
  68. Gradison M. Pelvic Inflammatory Diseases. American Academy of Family Physicians. 2012;(85):791-796.
  69. ВЗОМТ: Роль хламидийной инфекции (рациональные методы терапии). Информационный материал подготовлен д.м.н. Л.А. Марченко и к.м.н. Л.М. Ильиной 2006 г. по данным официальных рекомендаций Centers for Disease Control and Prevention (CDC), 2002 г.; статьи В.И. Кулакова А.С. Анкирской, С.М. Белобородова в ж. Гинекология (экстравыпуск: "Современная ЭРА терапии инфекций в гинекологии"), 2004; MMWR 2004;(53)42:983; WebMDHealthNews, 2005г.
  70. Kovacs GT., Westcott M, len Rusden, Asche V, King H, Haynes SE, Moore EK and Hall BE. A prospective single-blind trial of minocycline and doxycycline in the treatment of genital Chlamydia trachomatis infection in women. The medical journal of Australia. 1989;150(9):483-485.
  71. Romanowski B, Talbot H, Stadnyk M, Kowalchuk P and Bowie WR. Minocycline compared with doxycycline in the treatment of nongonococcal urethritis and mucopurulent cervicitis. Ann Intern Med. 1993;(119):16-22.
  72. Снарская Е.С., Олисова О.Ю., Шнахова Л.М., Каюмова Л.Н. Опыт применения миноциклина в лечении хламидийной инфекции. Инфекционные болезни. 2018;16(3):93-100. 
  73.  Bowie WR, Willetts Val,  Binns BA and  Brunham RC. Etiology of cervicitis and treatment with minocycline. Can J Infect Dis. 1993;4(2):95-100.
  74. Shao L, You C, Cao J, Jiang Y, Liu Y, Liu Q. High treatment failure rate is better explained by resistance gene detection than by minimum inhibitory concentration in patients with urogenital Chlamydia trachomatis infection. Int J Infect Dis. 2020;(96):121-127.
  75. Шипицына Е.В., Савичева А.М. Устойчивость Chlamydia trachomatis к антибиотикам. Журнал акушерства и женских болезней. 2002;51(4):77-83.
  76. Ridgway GL. Treatment of chlamydial genital infection. J. Antimicrob. Chemother. 1997;40:311-314.
  77. Somani J, Bhullar VB, Workowski KA, Farshy СE, Black СM. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis. 2000;181:1421-1427.
  78. Benamri I, Azzouzi M, Sanak K, Moussa A, Radouani F. An overview of genes and mutations associated with Chlamydiae species' resistance to antibiotics. Ann Clin Microbiol Antimicrob. 2021;20(1):59. 
  79. Sandoz KM and Rockey DD. Antibiotic resistance in Chlamydiae. Future Microbiol. 2010;(5):1427-1442.
  80. Wang SA, Papp JR, Stamm WE, Peeling RW, Martin DH and Holmes KK. Evaluation of antimicrobial resistance and treatment failures for Chlamydia trachomatis: a meeting report. J Infect Dis. 2005;191:917-923.
  81. O’Neill CE, Seth-Smith HM, Van Der Pol B, et al. Chlamydia trachomatis clinical isolates identified as tetracycline resistant do not exhibit resistance in vitro: whole-genome sequencing reveals a mutation in porB but no evidence for tetracycline resistance genes. Microbiology. 2013;159:748-756.
  82. Surico N, Tavassoli K. Treatment of pelvic inflammatory disease with combined piperacillin and minocycline therapy. Panminerva Med. 1990;32(4):184-9. 
  83. Kimura K, Hagiya H, Yamamoto N, Yoshida H, Akeda Y, Nishi I, Tomono K. Pasteurella multocida multiple intrapelvic abscesses in a young woman with uterine cervical cancer. J Infect Chemother. 2019;25(3):197-199. 
  84. Trabert B, Waterboer T, Idahl A et al. Antibodies Against Chlamydia trachomatis and Ovarian Cancer Risk in Two Independent Populations. JNCI: Journal of the National Cancer Institute. 2019;111(2):129-136.
  85. Franchini A, Beshoy I, Anwer F. The Role of Chlamydia Trachomatis in the  Pathogenesis of Cervical Cancer. Cureus. 2022;14(1): e21331.
  86. Fan H, Li L, Wijlaars L, Gilbert RE. Associations between use of macrolide antibiotics during pregnancy and adverse child outcomes: a systematic review and meta-analysis. PLoS One 2019;14:e0212212.
  87. Fan H, Gilbert R, O’Callaghan F, Li L. Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study. BMJ. 2020;368:m331.
  88. Phillips Campbell R, Kintner J, Whittimore J, Schoborg RV. Chlamydia muridarum enters a viable but non-infectious state in amoxicillin treated BALB/c mice. Microbes Infect 2012;14:1177-85.
  89. Wyrick PB. Chlamydia trachomatis persistence in vitro: an overview. J Infect Dis 2010;201(Suppl 2):S88–95.
  90. Edwards VL, Smith SB, McComb EJ, Tamarelle J, Ma B, Humphrys MS, et al. The cervicovaginal microbiota-host interaction modulates Chlamydia trachomatis infection. MBio 2019;10.
  91. Kroon SJ, Ravel J, Huston WM. Cervicovaginal microbiota, women’s health, and reproductive outcomes. Fertil Steril. 2018;110:327-38.
  92. Tamarelle J, Ma B, Gajer P, Humphrys MS, Terplan M, Mark KS, et al. Nonoptimal vaginal microbiota after Azithromycin treatment for Chlamydia trachomatis infection. J Infect Dis. 2020;221:627-35.
  93. Goulet V,  de Barbeyrac B,  Raherison S,  Prudhomme M,  Semaille C,  Warszawski J, et al. Prevalence of Chlamydia trachomatis: results from the first national population-based survey in France. Sex Transm Infect. 2010;86:263-270.
  94. Hazra A, Collison MW,  Davis AM. CDC Sexually Transmitted Infections Treatment Guidelines, 2021.
  95. LeFevre ML. Screening for chlamydia and gonorrhea: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;161:902-10.
  96. Screening for Chlamydia trachomatis and Neisseria gonorrhoeae during pregnancy: a health technology assessment Canadian agency for drugs and technologies in health; 2018 Nov.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*